CA
NZ
UK
AU
IND
US
The FDA's forthcoming decision regarding the legality of seven peptides, including BPC-157 and TB-500, could significantly influence the availability of these substances in the U.S. market. Current regulatory ambiguities have limited the accessibility of these peptides, which are often discussed in the context of …
Incannex Healthcare Inc. (NASDAQ: IXHL) has officially commenced participant screening for its DReAMzz Phase 2 dose confirmation study of IHL-42X, aimed at treating obstructive sleep apnea. This regulatory advance represents a important point for the company, which has experienced a significant 73.3% decline in …
The increasing popularity of GLP-1 medications, designed primarily for weight loss, is expected to drive a notable uptick in demand for Botox treatments, according to a Swiss aesthetics company. Patients using these medications often face the side effect of facial volume loss, commonly referred …
Inhibikase Therapeutics (NASDAQ: IKT) has achieved a key milestone with the U.S. Food and Drug Administration’s (FDA) decision to grant orphan drug designation for its leading candidate, IKT-001, aimed at treating pulmonary arterial hypertension (PAH). This designation is vital, considering the significant unmet medical …
Phreesia Inc's recent filing of Form DEF 14A has piqued interest among investors regarding its corporate governance practices. This critical document sheds light on upcoming proposals that could serve to enhance the company's operational transparency and accountability. As Phreesia navigates a highly competitive healthcare …
Medpace Holdings, a significant entity in the contract research organization (CRO) sector, has experienced a notable rebound in its financial performance, with its stock rising sharply as a result. The company reported strong bookings that exceeded market expectations, indicating a solid recovery from earlier …
This action signals strong belief in the company's potential, particularly as it prepares to embark on a key Phase 3 clinical trial. Scheduled for the second half of 2026, the trial will involve approximately 111 patients and aims to evaluate the efficacy of urcosimod, …
Bone Biologics (NASDAQ: BBLG) closed a private placement that generated roughly $3.0 million in gross proceeds, a cash infusion that stretches its operating runway through the second quarter of 2027 and funds the next phase of its NB1 spinal‑fusion program. The financing also attached …
A recent outbreak of Cyclospora presents immediate challenges to HHS Secretary Robert F. Kennedy Jr. as he attempts to reform the food system and rebuild trust in the CDC. The emergence of this foodborne illness resounds across the healthcare sector, particularly given the heightened …
The Supreme Court's recent Montgomery decision is set to significantly alter the operational environment for shippers in the trucking industry. This ruling addresses negligent selection claims against freight brokers, thereby extending the liability framework to include shippers' actions regarding the verification of their carriers …
Please wait processing your request...